The Experience Of Oxaliplatin-induced Peripheral Neuropathy And Its Impact On The Quality Of Life With Colorectal Cancer Patients

Objective1 To evaluate the impact of oxaliplatin-induced peripheral neuropathy on patients’ quality of life.2 To explore the patients’cognitive of peripheral neuropathy who used oxaliplatin, the impact on their daily life and coping, to provide guidance for health education of clinical nurses.Methods1 Investigated 134 colorectal cancer patients and completed the baseline survey and assessment of quality of life before the chemotherapy for the first time. After that, used PNQ and QLQ-CIPN20 to measure the severity of peripheral neuropathy and quality of life one week after oxaliplatin cumulative dose reached 200 mg/m2-.540 mg/m2、850mg/m2 or the end of treatment.2 13 colorectal cancer patients who suffered peripheral neuropathy participated in half-structured interviews. The data were analyzed by Giorgi’s analysis.Results1 113 patients with colorectal cancer were evaluated. Grade 2/3 paresthesias were seen in 7.1/31.1/64.1/56.5 and 1.8/10.7/10.9/34.8 percent of patients by cumulative dose 200 mg/m2、540 mg/m2、850mg/m2 and the end of treatment. Family living condition can influence the quality of life of patients with late course (p< 0.05) Results of The first survey of quality of life in patients with different residence were different significantly (p< 0.05)2 The scores of quality of life were significantly different at each cumulative dose(p< 0.001). And patients with different gender, programmes, administration and stages had similar change in the quality of life during chemotherapy.3 The severity of oxaliplatin-induced peripheral neuropathy were significantly different during chemotherapy (p< 0.05). As the course, symptoms of peripheral neuropathy got worse. The incidence of motor nerve damage was less than sensory nerve damage, and to a lesser extent.4 Patients with different administration routes had different severity of CIPN at the cumulative dose 200 mg/m2、540 mg/m2. However there was no difference at later sessions.5 Symptoms of peripheral neuropathy and quality of life scores were positively correlated. The quality of life got worse when symptoms of peripheral neuropathy got more severe.6 Four patients exited blunted touch sensation by Objective measurements. Temperature sensation was normal.7 Four themes were extracted, including experience of symtoms, influencing factors of symptoms experienced, outcomes of symptom experience and patients’response behavior.Conclusions1 The first symptom of Oxaliplatin-induced peripheral neuropathy is diverse. Symptom severity, duration and distress changed dynamically. Patients’ability to express of symptom experience can impact on the assessment of symptoms.2 Symptom experience of CIPN is affected by factors such as physical, psychological and environmental condition, social support. The social support can improve patients’quality of life.3 Oxaliplatin-induced peripheral neuropathy can influenced by temperature, physical and psychological condition and social support, leading to the change of body function, cognitive and behavior, ultimately affecting patients’quality of life.